中和性内分泌降低了血压,并改善了血管激素II诱导的高血压小鼠内皮功能
Eun Yi Oh1, Seonhee Byeon1, Soo-Kyoung Choi1
1Department of Physiology, Yonsei University College of Medicine, Seoul 03722, South Korea.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
|December 19, 2025
概括
通过通过TNF-α介导的eNOS抑制损害内皮功能,Endocan有助于高血压. 中和性内分泌抗体在高血压小鼠中改善了血压和血管功能,这表明内分泌作为治疗点.
科学领域:
- 心血管生物学 心血管生物学
- 内皮细胞功能 内皮细胞功能
- 高血压病理生理学 高血压病理生理学
背景情况:
- 内膜 (内皮细胞特异性分子-1) 是高血压中内皮功能障碍的潜在生物标志物.
- 它在血压调节中的精确作用以及它对高血压的贡献背后的机制需要进一步阐明.
研究的目的:
- 研究内分泌在血压调节和血管功能障碍中的作用.
- 为了澄清内分泌对高血压病理生理学的贡献.
主要方法:
- 在体内研究使用C57BL/6小鼠接受盐水,内分泌或血管新生素II (Ang II) 治疗,具有或没有中和性内分泌抗体.
- 评估静脉血压,中脉动脉中的血管功能,以及血清内分泌水平 (ELISA).
- 使用使用Ang II,endocan或TNF-α治疗的人类静脉内皮细胞 (HUVEC) 的体外研究,使用或不使用乙醇素,分析eNOS酸化和亚酸盐水平.
主要成果:
- 内分泌剂的使用增加了血压,并影响了内皮依赖放松的功能.
- 格II增加了血清内分泌细胞水平;中和内分泌细胞抗体降低了血压,改善了内皮功能.
- 恩多坎和Ang II降低了HUVEC中的eNOS酸化和亚酸盐水平;TNF-α抑制逆转了这些影响,表明TNF-α介导的机制.
结论:
- 恩多坎通过TNF-α介导的内皮氧化合成酶 (eNOS) 抑制促进内皮功能障碍和高血压.
- 向内分泌提供了对高血压和相关心血管疾病的潜在治疗策略.
相关概念视频
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
2.3K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.3K
01:25Antihypertensive Drugs: Direct Renin Inhibitors
1.2K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.2K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
879
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
879
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
2.4K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.4K
01:17Antihypertensive Drugs: Action of β1 Blockers
1.8K
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
1.8K
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
424
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
424